Cyclophosphamide versus Placebo in Scleroderma Lung Disease

20061,650 citationsJournal Articlebronze Open Access

Authors

Donald P. Tashkin · University of California, Los Angeles

Robert M. Elashoff · University of California, Los Angeles

Philip J. Clements · University of California, Los Angeles

Jonathan Goldin · University of California, San Francisco

Michael D. Roth · University of California, Los Angeles

Daniel E. Furst · University of California, Los Angeles

Edgar Arriola

Abstract

One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The effects on lung function were maintained through the 24 months of the study.

Topics & Keywords

Systemic Sclerosis and Related Diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Dermatologic Treatments and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 25, pp. 2655-2666

DOI: 10.1056/nejmoa055120

Field-Weighted Citation Impact: 49.92